Improvement of insulin resistance (IR) as contributor of diabetes remission and prevention is a well known beneficial effect of BS. We investigated the changes in IR and sensitivity (IS) in MO patients with newly diagnosed type 2 diabetes (DM) before and 2 years after BS and compared the changes to patients with either impaired fasting glucose or impaired glucose tolerance (IGT/IFG). We included 27 patients with DM (mean age 44±12 years, mean±SD, BMI 49± 10kg/m²) and 104 patients with IGT/IFG (mean age 41±11 years, BMI 47± 7kg/m²). All patients had a 75g oGTT, glucose and insulin levels were repeatedly measured for calculation of IR and IS indices (Table). BMI (p= 0.742) and age (p= 0.194) were not different between both groups. Indices are shown in the Table. Before BS, IR was significantly higher in DM for all indices (p<0.001), except for AUC insulin (p=0.631). After BS, there were no significant differences in AUC glucose (p= 0.454), HOMA (p=0.905) OGIS (p=0.355), Matsuda (p= 0.469) and the oral disposition Index (0.171). IGT/IFG patients had a higher AUC insulin (p= 0.024) and a lower IGI (p= 0.024) compared to DM. Newly diagnosed DM patients are more insulin resistant compared to IGT/IGF. BS reduces IR to the same level in both groups. Post-glucose challenge AUC insulin remained higher in IGT/IFG, indicating better pancreatic insulin secretion reserve, which might translate to better diabetes prevention.

J. Brix: None. E. Krzizek: None. A. Tura: None. G. Pacini: None. B. Ludvik: Advisory Panel; Self; Amgen Inc., AstraZeneca, Boehringer Ingelheim International GmbH, Sanofi, Takeda Development Centre Europe Ltd. Research Support; Self; Akebia Therapeutics, Eli Lilly and Company, Novartis AG, Novo Nordisk A/S. Speaker's Bureau; Self; Merck Sharp & Dohme Corp.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at